mRNA Therapy

mRNA Therapy represents an innovative therapeutic approach delivering messenger RNA encoding functional proteins into patient cells, enabling transient production of therapeutic proteins, antigens for vaccination, or genome editing machinery. This revolutionary modality exploits cellular translation machinery to produce desired proteins from exogenously delivered mRNA, with effects persisting days to weeks as mRNA degrades, providing self-limiting expression suitable for vaccines, protein replacement, or transient genome editing applications.

The biopharmaceutical industry achieved breakthrough success with COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna demonstrating unprecedented development speed, manufacturing scalability, and clinical efficacy, validating mRNA technology and accelerating broader therapeutic applications. Beyond vaccines, mRNA therapeutics under development include protein replacement for rare diseases, cancer immunotherapy encoding tumour antigens or immunostimulatory cytokines, and cardiovascular therapies. Technical considerations include mRNA design incorporating modified nucleosides reducing immunogenicity and enhancing stability, codon optimisation improving translation efficiency, plus delivery system development with lipid nanoparticles enabling cellular uptake while protecting mRNA from degradation. Manufacturing employs in vitro transcription enabling rapid production and straightforward sequence modifications. As delivery technologies improve tissue targeting, manufacturing scales economically, and clinical evidence expands, mRNA therapeutics continue advancing as a versatile platform transforming vaccine development and enabling previously impossible protein therapies.